Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma

Detalhes bibliográficos
Autor(a) principal: Coelho,S.M.
Data de Publicação: 2011
Outros Autores: Vaisman,F., Buescu,A., Mello,R.C.R., Carvalho,D.P., Vaisman,M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Brazilian Journal of Medical and Biological Research
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011000100011
Resumo: During thyroid tumor progression, cellular de-differentiation may occur and it is commonly accompanied by metastatic spread and loss of iodine uptake. Retinoic acid (RA) administration might increase iodine uptake in about 40% of patients, suggesting that RA could be a promising therapeutic option for radioiodine non-responsive thyroid carcinoma, although a prospective study with a long-term follow-up has not been reported. This was a clinical prospective study assessing the value of 13-cis-RA in patients with advanced thyroid carcinoma and its impact on major outcomes such as tumor regression and cancer-related death with a long-term follow-up of patients submitted to radioiodine (131I) therapy after RA administration. Sixteen patients with inoperable disease and no significant radioiodine uptake on post-therapy scan were selected. Patients were treated orally with 13-cis-RA at a dose of 1.0 to 1.5 mg·kg-1·day-1 for 5 weeks and then submitted to radioiodine therapy (150 mCi) after thyroxine withdrawal. A whole body scan was obtained 5 to 7 days after the radioactive iodine therapy. RECIST criteria were used to evaluate the response. An objective partial response rate was observed in 18.8%, a stable disease rate in 25% and a progression disease rate in 56.2%. Five patients died (62.5%) in the group classified as progression of disease. Progression-free survival rate (PFS) ranged from 72 to 12 months, with a median PFS of 26.5 months. RA may be an option for advanced de-differentiated thyroid cancer, due to the low rate of side effects.
id ABDC-1_8ea2449cdbc31f3f300e6f5b71bfb9e1
oai_identifier_str oai:scielo:S0100-879X2011000100011
network_acronym_str ABDC-1
network_name_str Brazilian Journal of Medical and Biological Research
repository_id_str
spelling Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinomaThyroid cancerRetinoic acidRadioiodine therapyDuring thyroid tumor progression, cellular de-differentiation may occur and it is commonly accompanied by metastatic spread and loss of iodine uptake. Retinoic acid (RA) administration might increase iodine uptake in about 40% of patients, suggesting that RA could be a promising therapeutic option for radioiodine non-responsive thyroid carcinoma, although a prospective study with a long-term follow-up has not been reported. This was a clinical prospective study assessing the value of 13-cis-RA in patients with advanced thyroid carcinoma and its impact on major outcomes such as tumor regression and cancer-related death with a long-term follow-up of patients submitted to radioiodine (131I) therapy after RA administration. Sixteen patients with inoperable disease and no significant radioiodine uptake on post-therapy scan were selected. Patients were treated orally with 13-cis-RA at a dose of 1.0 to 1.5 mg·kg-1·day-1 for 5 weeks and then submitted to radioiodine therapy (150 mCi) after thyroxine withdrawal. A whole body scan was obtained 5 to 7 days after the radioactive iodine therapy. RECIST criteria were used to evaluate the response. An objective partial response rate was observed in 18.8%, a stable disease rate in 25% and a progression disease rate in 56.2%. Five patients died (62.5%) in the group classified as progression of disease. Progression-free survival rate (PFS) ranged from 72 to 12 months, with a median PFS of 26.5 months. RA may be an option for advanced de-differentiated thyroid cancer, due to the low rate of side effects.Associação Brasileira de Divulgação Científica2011-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011000100011Brazilian Journal of Medical and Biological Research v.44 n.1 2011reponame:Brazilian Journal of Medical and Biological Researchinstname:Associação Brasileira de Divulgação Científica (ABDC)instacron:ABDC10.1590/S0100-879X2010007500120info:eu-repo/semantics/openAccessCoelho,S.M.Vaisman,F.Buescu,A.Mello,R.C.R.Carvalho,D.P.Vaisman,M.eng2011-01-17T00:00:00Zoai:scielo:S0100-879X2011000100011Revistahttps://www.bjournal.org/https://old.scielo.br/oai/scielo-oai.phpbjournal@terra.com.br||bjournal@terra.com.br1414-431X0100-879Xopendoar:2011-01-17T00:00Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)false
dc.title.none.fl_str_mv Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma
title Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma
spellingShingle Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma
Coelho,S.M.
Thyroid cancer
Retinoic acid
Radioiodine therapy
title_short Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma
title_full Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma
title_fullStr Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma
title_full_unstemmed Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma
title_sort Follow-up of patients treated with retinoic acid for the control of radioiodine non-responsive advanced thyroid carcinoma
author Coelho,S.M.
author_facet Coelho,S.M.
Vaisman,F.
Buescu,A.
Mello,R.C.R.
Carvalho,D.P.
Vaisman,M.
author_role author
author2 Vaisman,F.
Buescu,A.
Mello,R.C.R.
Carvalho,D.P.
Vaisman,M.
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Coelho,S.M.
Vaisman,F.
Buescu,A.
Mello,R.C.R.
Carvalho,D.P.
Vaisman,M.
dc.subject.por.fl_str_mv Thyroid cancer
Retinoic acid
Radioiodine therapy
topic Thyroid cancer
Retinoic acid
Radioiodine therapy
description During thyroid tumor progression, cellular de-differentiation may occur and it is commonly accompanied by metastatic spread and loss of iodine uptake. Retinoic acid (RA) administration might increase iodine uptake in about 40% of patients, suggesting that RA could be a promising therapeutic option for radioiodine non-responsive thyroid carcinoma, although a prospective study with a long-term follow-up has not been reported. This was a clinical prospective study assessing the value of 13-cis-RA in patients with advanced thyroid carcinoma and its impact on major outcomes such as tumor regression and cancer-related death with a long-term follow-up of patients submitted to radioiodine (131I) therapy after RA administration. Sixteen patients with inoperable disease and no significant radioiodine uptake on post-therapy scan were selected. Patients were treated orally with 13-cis-RA at a dose of 1.0 to 1.5 mg·kg-1·day-1 for 5 weeks and then submitted to radioiodine therapy (150 mCi) after thyroxine withdrawal. A whole body scan was obtained 5 to 7 days after the radioactive iodine therapy. RECIST criteria were used to evaluate the response. An objective partial response rate was observed in 18.8%, a stable disease rate in 25% and a progression disease rate in 56.2%. Five patients died (62.5%) in the group classified as progression of disease. Progression-free survival rate (PFS) ranged from 72 to 12 months, with a median PFS of 26.5 months. RA may be an option for advanced de-differentiated thyroid cancer, due to the low rate of side effects.
publishDate 2011
dc.date.none.fl_str_mv 2011-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011000100011
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2011000100011
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0100-879X2010007500120
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica
dc.source.none.fl_str_mv Brazilian Journal of Medical and Biological Research v.44 n.1 2011
reponame:Brazilian Journal of Medical and Biological Research
instname:Associação Brasileira de Divulgação Científica (ABDC)
instacron:ABDC
instname_str Associação Brasileira de Divulgação Científica (ABDC)
instacron_str ABDC
institution ABDC
reponame_str Brazilian Journal of Medical and Biological Research
collection Brazilian Journal of Medical and Biological Research
repository.name.fl_str_mv Brazilian Journal of Medical and Biological Research - Associação Brasileira de Divulgação Científica (ABDC)
repository.mail.fl_str_mv bjournal@terra.com.br||bjournal@terra.com.br
_version_ 1754302939350958080